Eyenovia (EYEN) Receives a Hold from Oppenheimer

Oppenheimer analyst Esther Rajavelu maintained a Hold rating on Eyenovia (EYENResearch Report) today. The company’s shares closed last Monday at $2.34.

According to TipRanks.com, Rajavelu is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -13.7% and a 34.5% success rate. Rajavelu covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Teva Pharmaceutical Industries, and Arrowhead Pharmaceuticals.

Currently, the analyst consensus on Eyenovia is a Moderate Buy with an average price target of $16.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.98 and a one-year low of $1.11. Currently, Eyenovia has an average volume of 59.27K.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EYEN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The company was founded on March 12, 2014 and is headquartered in New York, NY.